Med Life Sa · BVB:M
Med Life Sa — H1 2024 Earnings Presentation
17 slides from Med Life Sa's earnings presentation, Aug 30, 2024
Slide 1: H1 2024 Results Presentation
H1 2024 Results Presentation 30 August 2024 www.medlife.ro / www.medlifeinternational.com www.medlife.ro www.medlifeinternational.com
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 6mo 2024 Highlights • • Key messages Outlook 2 6mo 2024 • Consolidated Statement of Profit and Loss AGENDA • Consolidated Statement of Financial Position Financial Results • Consolidated Statement of Cash Flow 3 Q&A Session 3
Slide 4: 6mo 2024 Highlights
6mo 2024 Highlights • Key Messages • Outlook 1
Slide 5: Key messages
Key messages Consistent growth of the financial and operational performance of the Group, showing the positive impact of integrating companies into the group and the investments made in recent years, which have begun to show their efficiency. Consolidated pro-forma Turnover of RON 1.3 billion, up by
Slide 6: Outlook
Outlook Strategic priorities: • inauguration of the Medici`s Hospital in Timisoara and MedLife Hospital in Craiova, expected to be operational by the end of the year; • continued development of the MedLife Park project. Focus on: • optimizing the operational flows and procedures within the Group, in
Slide 7: 6mo 2024 Financial Results
6mo 2024 Financial Results • Consolidated Statement of Profit and Loss • Pro-forma Figures • QoQ Evolution • Operational KPIs • OPEX Evolution • Consolidated Statement of Financial Position • Debt Position • Consolidated Statement of Cash Flow 2
Slide 8: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss 6M 2023 6M 2024 Pro-forma 6m 2024 % var. % var. IFRS IFRS adjusted Pro-forma Consolidated pro-forma Turnover of RON 1.3bn, up by 24% YoY, Gross sales 1,066,209,218 1,310,400,099 22.9 % 9,271,380 1,319,671,479 23.8 % with a strong evolution in almost Net sale
Slide 9: Pro-forma Figures
Pro-forma Figures Pro-forma Revenues Pro-forma EBITDA 1,310,400,099 199,554,857 193,209,066 1,243,731,988 9,271,380 1,452,967 4,892,824 -75,939,491 6m 2024 Acquisitions One-off expenses 6m 2024 6m 2024 Acquisitions National Program 6m 2024 IFRS Pro-forma IFRS Reclass Pro-forma From IFRS Revenues to
Slide 10: QoQ Evolution
QoQ Evolution 120 EBITDA evolution 98.1 19.0% 100 17.2% 95.1 17.0% 72.2 74.7 75.8 80 67.2 71.2 15.2% 63.5 62.4 EBITDA 14.1% 14.3% 15.0% (RON m) 60 13.5% 48.6 13.5% 14.4% 12.5% 12.2% 13.0% EBITDA 40 margin (%) 20 10.3% 11.0% 0 9.0% Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24
Slide 11: Operational KPIs
Operational KPIs 6m 2023 6m 2024 % Total Business line Category % var. IFRS IFRS IFRS Sales Revenue 397,318,224 487,721,487 22.8% 37.2% Solid growth of 23% in Revenues, out of which Clinics Visits 1,874,937 2,097,031 13.5% 17% organic growth, with all business lines Average fee 211.9 232.6 8.2% Reve
Slide 12: OPEX Evolution
OPEX Evolution % OPEX % Sales 6m 2023 6m 2024 6m ‘23 6m ‘24 6m ‘23 6m ‘24 % var. % var. % var. IFRS IFRS IFRS IFRS IFRS IFRS Consumable materials and repair materials 186,568,449 234,124,014 25.5% 18.2% 18.9% 0.7 p.p 17.5% 17.9% 0.4 p.p Commodities 103,737,029 109,887,241 5.9% 10.1% 8.9% -1.2 p.p 9.
Slide 13: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position 31 December 2023 30 June 2024 % var. IFRS IFRS Non-current assets 2,102,828,820 2,177,694,307 3.6% Current assets, excluding Cash and cash equivalents 433,237,518 462,695,647 6.8% Cash and cash equivalents 100,271,093 130,711,618 30.4% TOTAL ASSETS 2,636,
Slide 14: Debt Position
Debt Position 31 December 2023 30 June 2024 % var. IFRS IFRS Net debt to Pro-forma EBITDA Leasing liabilities ratio decreased from 4.6x to 4.0x, Current portion – Leasing 99,589,187 100,025,086 0.4% supported mainly by the increase Long term portion - leasing 309,158,946 314,392,008 1.7% in EBITDA l
Slide 15: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow 30 June 2023 30 June 2024 % var. IFRS IFRS Net income before taxes 12,268,030 28,959,140 136.1% Adjustments for non-monetary items 127,197,561 165,938,612 30.5% Operating cash flow before working capital and other monetary changes 139,465,591 194,897,752 39.7% Cas
Slide 16: Q&A session
Q&A session 3
Slide 17: Thank you!
MedLife Group 365, Calea Grivitei, Bucharest investors@medlife.ro Thank you!